Neoantigen Cancer Vaccine Candidate TG4050 Development Continues

Transgene and NEC Corporation today announced the signing of a further development collaboration agreement to continue the clinical evaluation of the individualized neoantigen cancer vaccine TG4050.

TG4050 is currently being evaluated in a randomized multicenter Phase I trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers. Based on promising data obtained in this Phase I trial, Transgene and NEC are preparing a randomized Phase I/II extension of this trial slated to start in 2024.

This new trial builds on compelling first signs of efficacy and induction of specific T-cell responses to generate a comprehensive set of immunological and clinical data to demonstrate the potential of TG4050 further.

Additional immunological and clinical data from the Phase I trial is expected at a scientific conference in the first half of 2024.

Alessandro Riva, Chairman and CEO of Transgene, commented in a press release, "We are pleased to announce the extension of our agreement with NEC, which marks a significant milestone in our collaboration."

"We look forward to continuing to treat patients with our individualized cancer vaccine TG4050. The compelling initial Phase I data presented with NEC at ASCO 2023 showed that all evaluable patients treated with TG4050 monotherapy developed a specific immune response and remained disease-free."

"Our joint clinical development plan builds on these promising data in a setting where there is no approved treatment to prevent patient relapse after adjuvant chemoradiotherapy."

"We believe that TG4050, by combining a powerful and immunogenic viral vector with an extremely sophisticated neoantigen selection tool, has the potential to address major medical needs in the adjuvant treatment of solid tumors."

TG4050 is based on Transgene's viral vector-based myvac® platform and powered by NEC's cutting-edge AI capabilities for identifying and predicting the most immunogenic neoantigens.